Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Skin and subcutaneous tissue disorders – page 26

  • 849 clinical trials
  • 267 recruiting
  • 359 conditions
  • 25 countries

Conditions in this area

359 conditions with trials, the busiest first

Dermatitis atopic89Malignant melanoma79Systemic lupus erythematosus63Psoriasis54Hidradenitis47Psoriatic arthropathy46Systemic scleroderma40Metastatic malignant melanoma32Vitiligo24Hereditary angioedema22Chronic spontaneous urticaria19Malignant melanoma stage III17Dermatomyositis16Non-small cell lung cancer15Alopecia areata14Cutaneous lupus erythematosus14Rheumatoid arthritis14Basal cell carcinoma12Diabetic foot12Malignant melanoma stage IV12Actinic keratosis11Hepatocellular carcinoma11Neurodermatitis11Squamous cell carcinoma of skin11+335

Clinical trials in Skin and subcutaneous tissue disorders

849 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

849 clinical trials

Hidradenitis

Not yet recruiting

Adalimumab, Doxycycline, and Resorcinol for Adults with Early Hidradenitis Suppurativa at High Risk of Progression to Severe Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Adalimumab
  • Sponsor:Gentofte Hospital

Acquired C1 inhibitor deficiency

Not yet recruiting

Efficacy and Safety of Berotralstat for Preventing Angioedema Attacks in Patients with Acquired Angioedema due to C1 Inhibitor Deficiency

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Berotralstat
  • Sponsor:Policlinico San Donato S.p.A.

Cutaneous T-cell lymphoma

Not yet recruiting

Topical delgocitinib safety study in patients with cutaneous T‑cell lymphoma (mycosis fungoides)

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Sponsor:Region Midtjylland

Malignant melanoma stage IV+1

Not yet recruiting

Phase Ib/II study of momelotinib with nivolumab or pembrolizumab in unresectable stage III/IV cutaneous melanoma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Karolinska University Hospital

Systemic scleroderma

Not yet recruiting

Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Acute myeloid leukaemia+1

Not yet recruiting

Safety and feasibility study of CARCIK‑CD123/33 cell therapy in adult and pediatric patients with relapsed or refractory AML and BPDCN

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Fondazione IRCCS San Gerardo Dei Tintori

Lichen sclerosus

Not yet recruiting

A Phase 3 Study of Delgocitinib Cream to Evaluate Efficacy and Safety in Adult Women with Lichen Sclerosus

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Leo Pharma A/S

Systemic lupus erythematosus

Not yet recruiting

Obinutuzumab in patients with pure class V lupus nephritis (systemic lupus erythematosus membranous nephropathy) – phase II trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Squamous cell carcinoma of skin

Not yet recruiting

Phase II Study of Cemiplimab to Spare Surgery in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Fondazione GONO Plus

Systemic scleroderma

Not yet recruiting

Safety and Efficacy of MTX-474 in Adults with Diffuse Cutaneous Systemic Sclerosis (dcSSc) – A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glucose Monohydrate
  • Sponsor:Mediar Therapeutics Inc.

IPEX syndrome

Not yet recruiting

Safety and Efficacy Study of FOXP3‑T4 and Aldesleukin in Patients with IPEX Syndrome

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Aldesleukin
  • Sponsor:Assistance Publique Hopitaux De Paris

Systemic scleroderma+1

Not yet recruiting

Study of CC-97540 (CD19‑Targeted NEX‑T CAR T) versus drug combination in adults with active systemic sclerosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Pembrolizumab57 clinical trialsNivolumab33 clinical trialsSodium Chloride22 clinical trialsDeucravacitinib19 clinical trialsCemiplimab18 clinical trialsUpadacitinib17 clinical trialsIpilimumab15 clinical trialsRituximab13 clinical trialsCyclophosphamide12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.